Suppr超能文献

草药(当归加积散)治疗原发性痛经的疗效与安全性:一项随机、双盲、安慰剂对照、平行组、多中心试验的研究方案

Efficacy and safety of herbal medicine (Dangguijagyag-san) for primary dysmenorrhea: study protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial.

作者信息

Woo Hye Lin, Ji Hae Ri, Kim Siin, Suh Hae Sun, Kim Kwan-Il, Lee Jin Moo, Park Kyoung Sun

机构信息

Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea.

College of Pharmacy, Pusan National University, Busan, Republic of Korea.

出版信息

Integr Med Res. 2020 Jun;9(2):100394. doi: 10.1016/j.imr.2020.02.002. Epub 2020 Feb 21.

Abstract

BACKGROUND

Dangguijagyag-san, also known as Dangguishaoyao-san in Chinese and Toki-shakuyakui-san in Japanese, has been frequently used to treat symptoms associated with dysmenorrhea. The purpose of this trial is to evaluate the efficacy and safety of the herbal medicine, Dangguijagyag-san, relative to those of active control, Gamisoyo-san, and a placebo control for primary dysmenorrhea.

METHODS

This protocol details a randomized, double-blind, parallel-group, multi-center, investigator-initiated, controlled trial evaluating treatment of primary dysmenorrhea. Two hundred and forty participants will be randomly divided into one of three groups: 1) the Dangguijagyag-san experimental group (EG) (n = 105), 2) the Gamisoyo-san active control group (ACG) (n = 30), and 3) the placebo control group (PCG) (n = 105). The interventions will be administered for two menstrual cycles, and the follow-up will be carried out for the following six menstrual cycles. The primary outcomes are difference in response rates between the EG and the ACG (non-inferiority comparison) and difference in changes from baseline in average pain intensity measured by the visual analogue scale between the EG and PCG (superiority comparison). The secondary outcomes are pain scores derived from pain assessment tools (verbal multidimensional scoring system, retrospective symptom scale, and short form McGill pain questionnaire), dosage of analgesics, pattern diagnosis questionnaires, and short form 36 health survey. Adverse events and vital signs will be checked at every visit, and laboratory tests will be performed for safety evaluation.

DISCUSSION

The results of this clinical trial will offer evidence for the efficacy and safety of Dangguijagyag-san for primary dysmenorrhea.

TRIAL REGISTRATION

Clinical Research Information Service of Korea: KCT0003005.

摘要

背景

当归芍药散,在中国称为当归芍药散,在日本称为芍药甘草汤,常用于治疗痛经相关症状。本试验的目的是评估中药当归芍药散相对于阳性对照药加味逍遥散和安慰剂对照治疗原发性痛经的疗效和安全性。

方法

本方案详细描述了一项随机、双盲、平行组、多中心、研究者发起的对照试验,以评估原发性痛经的治疗效果。240名参与者将被随机分为三组之一:1)当归芍药散实验组(EG)(n = 105),2)加味逍遥散阳性对照组(ACG)(n = 30),3)安慰剂对照组(PCG)(n = 105)。干预措施将持续两个月经周期,并在接下来的六个月经周期进行随访。主要结局指标是EG组和ACG组之间的有效率差异(非劣效性比较),以及EG组和PCG组之间通过视觉模拟量表测量的平均疼痛强度与基线相比的变化差异(优效性比较)。次要结局指标是疼痛评估工具(语言多维评分系统、回顾性症状量表和简化麦吉尔疼痛问卷)得出的疼痛评分、镇痛药用量、证型诊断问卷和36项简明健康调查。每次访视时检查不良事件和生命体征,并进行实验室检查以评估安全性。

讨论

本临床试验结果将为当归芍药散治疗原发性痛经的疗效和安全性提供证据。

试验注册

韩国临床研究信息服务中心:KCT0003005。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3176/7152655/1be3757a8551/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验